Klotho Neurosciences, Inc. (KLTO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Klotho Neurosciences, Inc. (KLTO) has a cash flow conversion efficiency ratio of -0.110x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.09 Million) by net assets ($9.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Klotho Neurosciences, Inc. balance sheet independence to measure how much of total assets are equity-financed.
Klotho Neurosciences, Inc. - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Klotho Neurosciences, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Klotho Neurosciences, Inc. investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Klotho Neurosciences, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Klotho Neurosciences, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Polychem Indonesia Tbk
JK:ADMG
|
-0.015x |
|
iBio, Inc. Common Stock
NASDAQ:IBIO
|
-0.093x |
|
Dinamik Isi Makina Yalitim Malzemeleri Sanayi ve Ticaret AS
IS:DNISI
|
-0.013x |
|
SuperCom Ltd
F:50S
|
-0.056x |
|
Poujoulat S.A.
PA:ALPJT
|
-0.134x |
|
Optivision Technology
TWO:3666
|
0.002x |
|
Genie Music Corporation
KQ:043610
|
0.050x |
|
Sam-A Pharm. Co. Ltd
KQ:009300
|
0.001x |
Annual Cash Flow Conversion Efficiency for Klotho Neurosciences, Inc. (2021–2024)
The table below shows the annual cash flow conversion efficiency of Klotho Neurosciences, Inc. from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see Klotho Neurosciences, Inc. stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.19 Million | $-2.95 Million | -2.486x | -217.99% |
| 2023-12-31 | $571.72K | $-446.92K | -0.782x | -53.74% |
| 2022-12-31 | $1.18 Million | $-599.57K | -0.508x | -83.75% |
| 2021-12-31 | $1.03 Million | $-284.02K | -0.277x | -- |
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer's disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig's disease. The company was formerly known as Anew Medical, Inc. and changed it… Read more